Recent Advances in Immune Checkpoint Inhibitors for Triple-Negative Breast Cancer.

Immunotargets Ther · 2025 · PMC11974553 · PMID 40196378

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

7 The subgroup analysis presented at the 2024 San Antonio Breast Cancer Symposium (SABCS) showed that, consistent with the ITT population, pembrolizumab demonstrated a positive trend in OS across subgroups, including those defined by PD-L1 expression, nodal status, overall stage, and baseline T2N0 status.

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.